Contract development and manufacturing organisation Benuvia Operations LLC announced on Thursday that it has entered into licensing and supply agreements with Rio de Janeiro-based Medra Brasil Medicamentos LTDA, a distributor of pharmaceutical medicinal cannabis products.

Under the licensing agreement Medra Brasil will become the exclusive supplier for SYNDROS (dronabinol), oral solution, CII in Brazil following approval by the Brazilian Health Regulatory Agency (Anvisa). SYNDROS is the first and only FDA-approved CII tetrahydrocannabinol (THC) liquid cannabinoid used in adults to treat Chemotherapy Induced Nausea and Vomiting (CINV) and Anorexia Associated Weight Loss and Aids (AAWLA).

Benuvia has also signed a supply agreement with Medra Brasil to support the development of new Medra Brasil CBD products, and will become a key Medra supplier.

Terry Novak, Benuvia CEO, said: "We are thrilled to announce our first out-licensing partnership with Medra Brasil to bring SYNDROS to the people of Brazil. This is an important milestone for Benuvia as we expand our global partnerships to further commercialise SYNDROS and all our cannabinoid and psychedelic products and services."